Polyclonal Antibodies Market Trends

  • Report ID: 5659
  • Published Date: Apr 29, 2024
  • Report Format: PDF, PPT

Polyclonal Antibodies Market Trends

Growth Drivers

  • Technological advancements in antibody production - The continuous evolution of polyclonal antibody production technologies, along with several technological advancements, has lucratively improved the efficiency and demand of manufacturing processes while ensuring a consistent supply of high-quality polyclonal antibodies to consumers. According to a report, in the U.S., more than 24 million people are affected by more than 80 different types of autoimmune diseases. Moreover, innovations in antibody purification, expression systems, production platforms, and many more have streamlined their manufacturing procedures while reducing production costs and improving overall product quality. This has had a substantial effect on market growth as pharmaceutical and biotechnology companies are increasingly turning towards advanced technologies for the development and production of polyclonal antibodies. In addition, the increasing incidence of diseases such as rheumatoid arthritis, lupus, and multiple sclerosis has led to a surge in research and development activities that are focused on the demand for polyclonal antibodies for effective treatment. According to the American Autoimmune Related Diseases Association (AARDA), approximately 50 million Americans suffered from autoimmune diseases as of 2021.
  • Increase in cancer disease - Since polyclonal antibodies are produced by B cells in response to an antigen, such as malignant cells, the market share for these antibodies is slated to expand at a lucrative rate, which can be attributed to the rise in cancer cases. According to a report, there were about 20 million new cancer cases in 2022 and about 9.7 million deaths caused by cancer. Furthermore, driven by the disease's global rise, there is a strong need for both accurate and effective cancer treatments as well as diagnostics. The production of high-quality antibodies in large quantities has also become easier and more economical with the advent of new technology for the production and purification of polyclonal antibodies. This has increased the range of polyclonal antibodies for clinical as well as research applications, which has further fueled market demand.
  • Research and development in life sciences - The ongoing advancements in life sciences research contribute substantially to the growth of the polyclonal antibodies market. Polyclonal antibodies play a crucial role in various research applications, such as Western blotting, immunohistochemistry, and flow cytometry. The expanding scope of life sciences research, including genomics, proteomics, and cell biology, demands reliable and versatile tools like polyclonal antibodies. This increasing demand for antibodies in research applications fuels the growth of the market, with academic institutions, research laboratories, and biotechnology companies actively contributing to the expanding landscape.

Challenges

  • Availability of different options - Polyclonal antibodies, which are derived from the immune responses of multiple organisms, can lead to several differences in the antibody composition, and this variability can highly impact the reproducibility and consistency of such experimental results. This can pose many challenges in research and diagnostic applications.Furthermore, the dominance of monoclonal antibodies in certain therapeutic and diagnostic applications poses a challenge for the polyclonal antibody landscape. Monoclonal antibodies also offer a much more targeted approach, coupled with higher specificity and reduced variability compared to polyclonal antibodies. This can act as a restraining factor for the growth rate of this sector.
  • High competition from monoclonal antibodies can cause hindrance.
  • Increasing ethical and regulatory concerns

Polyclonal Antibodies Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

8%

Base Year Market Size (2023)

USD 10 Billion

Forecast Year Market Size (2036)

USD 26 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5659
  • Published Date: Apr 29, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of barge transportation was over USD 10 Billion.

The market size for the polyclonal antibodies market is projected to cross USD 26 Billion by the end of 2036 expanding at a CAGR of 8% during the forecast period i.e., between 2024-2036.

The major players in the market are Thermo Fisher Scientific Inc., Merck KGaA, Bio-Rad Laboratories, Inc., GenScript Biotech Corporation, BioLegend, Inc., Cell Signaling Technology, Inc., Rockland Immunochemicals Inc., Agilent Technologies, Inc., Fitzgerald Industries International, Fujifilm Corporation, Wako Pure Chemical Industries, Ltd., Cosmo Bio Co., Ltd., MBL International Corporation, Abnova Corporation., and others.

In terms of type, the human source segment is anticipated to account for the largest market share of 54% during 2024-2036.

The Asia Pacific polyclonal antibodies sector is poised to hold the highest share of 47% by 2036.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample